Effects of epoetin on vascular biology

Nephrology Dialysis Transplantation

Volumn 14, Issue SUPPL. 2, 1999, Pages 46-49

  Vaziri, N D ^a,b   Ateshkadi, A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Epoetin; Haemostatis system; Hypertension; Systemic blood pressure

Indexed keywords

CALCIUM ION; RECOMBINANT ERYTHROPOIETIN; VASOACTIVE AGENT;

BLOOD PRESSURE; CALCIUM CELL LEVEL; CELL GROWTH; CONFERENCE PAPER; DRUG EFFECT; DRUG MECHANISM; ERYTHROPOIESIS; HEMOSTASIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE DYSFUNCTION; UREMIA; VASCULARIZATION;

ANIMALS; ARGININE; BLOOD PRESSURE; ENDOTHELINS; ERYTHROPOIETIN; HEMATOCRIT; HEMOSTASIS; HUMANS; NITRIC OXIDE;

EID: 0032890547     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Abraham PA, Macres MG. Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. J Am Soc Nephrol 1991; 2: 927-936
2. Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW. Hypertension following erythropoietin therapy in anemic hemodialysis patients. Am J Hypertension 1990; 3: 947-955
3. Raine AEG, Roger SD. Effects of erythropoietin on BP. Am J Kidney Dis 1991; 18: 76-83
4. Vaziri ND, Zhou XJ, Naqvi F et al. Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure. Am J Physiol (Endocrinol Metab) 1996; 23: E113-E122
5. Raine AEG. Hypertension, blood viscosity and cardiovascular morbidity in renal failure: implications of erythropoietin therapy. Lancet 1988; 1: 97-99
6. Steffen HM, Brunner R, Muller R et al. Peripheral hemodynamics, blood viscosity, and the renin-angiotensin system in hemodialysis patients under therapy with recombinant human erythropoietin. Contrib Nephrol 1989; 76: 292-298
7. Neff MS, Kim KE, Persoff M, Onesti G, Swartz C. Hemodynamics of uremic anemia. Circulation 1971; 43: 876-883
8. Martin J, Moncada S. Blood pressure, erythropoietin and nitric oxide (letter). Lancet 1988; 1: 644
9. Kaupke CJ, Kim S, Vaziri ND. Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy. J Am Soc Nephrol 1994; 4: 1874-1878
10. Label M, Kingma I, Grose JH, Langlois S. Hemodynamic and hormonal changes during erythropoietin therapy in hemodialysis patients. J Am Soc Nephrol 1998; 9: 97-104
11. Bode-Boger SM, Boger RH, Kuhn M, Radermacher J, Frolich JC. Endothelin release and shift of prostaglandin balance are involved in the modulation of vascular tone by recombinant erythropoietin. J Cardiovasc Pharmacol 1992; 20: S25-S28
12. Hand MF, Haynes WG, Johnstone HA, Anderton JL, Webb DJ. Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure. Kidney Int 1995; 48: 806-813
13. Vaziri ND, Zhou XJ, Smith J, Oveisi F, Baldwin K, Purdy RE. In vivo and in vitro pressor effects of erythropoietin in rats. Am J Physiol (Renal Fluid Electrolyte Physiol) 1995; 269: F838-F845
14. Eggena P, Willsey P, Jamgotchian N et al. Influence of recombinant human erythropoietin on blood pressure and renin-angiotensin systems. Am J Physiol 1991; 261: E642-E646
15. Carlini R, Obialo CI, Rothstein M. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients. Am J Hypertension 1993; 6: 103-107
16. Carlini RG, Dusso AS, Obialo CI, Alvarez UM, Rothstein M. Recombinant human erythropoietin (rHu EPO) increases endothelin-1 release by endothelial cells. Kidney Int 1993; 43: 1010-1014
17. Bode-Boger SM, Boger RH, Kuhn M, Radermacker J, Frolich JC. Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int 1996; 50: 1255-1261
18. Katoh K, Mizuno K, Hashimoto S et al. Direct evidence for erythropoietin-induced release of endothelin from peripheral vascular tissue. Life Sci 1994; 54: 253-259
19. Takahashi K, Totsune K, Imai Y et al. Plasma concentrations of immunoreactive endothelin in patients with chronic renal failure treated with recombinant human erythropoietin. Clin Sci 1993; 84: 47-50
20. Zhou XJ, Panidan D, Wang XQ, Vaziri ND. Erythropoietin-induced hypertension in rat is not mediated by alterations of plasma endothelin, vasopressin, or atrial natriuretic peptide levels. J Am Soc Nephrol 1997; 8: 901-905
21. Hon G, Vaziri ND, Kaupke CJ, Tehranzadeh A, Barton CH. Lack of a fast-acting effect of erythropoietin on arterial blood pressure and endothelin level. Artif Org 1995; 19: 188-191
22. Lai KN, Lai SF, Leung JCK, Law E, Nicholls MG. Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysis. Nephron 1991; 57: 394-400
23. del Castillo D, Raij L, Shultz PJ, Tolins JP. The pressor effect of recombinant human erythropoietin is not due to decreased activity of the endogenous nitric oxide system. Nephrol Dial Transplant 1995; 10: 505-508
24. Van Geet C, Van Damme-Lombaerts R, Vanrusselt M, de Mol A. Recombinant human erythropoietin increases blood pressure, platelet aggregability and platelet free calcium mobilization in uremic children: a possible link. Thromb Haemost 1990; 64: 7-10
25. Neusser M, Tepel M, Zidek W. Erythropoietin increases cytosolic free calcium concentration in vascular smooth muscle cells. Cardiovasc Res 1993; 27: 1233-1236
26. Hiedenreich S, Rahn KH, Zidek W. Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int 1991; 39: 259-265
27. Carlini PG, Reyes AA, Rothstein M. Recombinant erythropoietin stimulates angiogenesis in vitro. Kidney Int 1995; 47: 740-745
28. Gogusev J, Zhu D-L, Herembert T, Ammarguellat FA, Marche P, Drueke T. Effect of erythropoietin on DNA synthesis, protooncogene expression and phospholipase C activity in rat vascular smooth muscle cell. Biochem Biophys Res Commun 1994; 199: 977-983
29. Ammarguellat F, Gogusev J, Drueke TB. Direct effect of erythropoietin on rat vascular smooth muscle cell via a putative erythropoietin receptor. Nephrol Dial Transplant 1996; 11: 687-692
30. Kaupke CJ, Butler GC, Vaziri ND. Effect of recombinant human erythropoietin on platelet production in dialysis patients. J Am Soc Nephrol 1993; 3: 1672-1679